UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): October 19, 2018
Nexien
BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Commission File No.: 0-55320
| Delaware | 26-2049376 | |
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |
| 4340 E Kentucky Ave, Suite 206, Glendale, CO | 80246 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (303) 495-7583
Intiva BioPharma Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 8.01 Other Events.
Effective October 19, 2018, the common stock of the registrant, Nexien BioPharma, Inc., will trade under the symbol, “NXEN.” The new CUSIP number for the common stock is 65343D100. A press release announcing the new trading symbol is included as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Regulation S-K Number |
Document | |
| 99.1 | Press release dated October 19, 2018 |
| 2 |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEXIEN BIOPHARMA, INC. | |
| /s/: Alain Bankier | |
| Alain Bankier, Chief Executive Officer | |
| October 19, 2018 |
| 3 |
EXHIBIT INDEX
Regulation S-K Number |
Document | |
| 99.1 | Press release dated October 19, 2018 |
| 4 |
NEXIEN BioPharma Inc.
Announces Symbol Change to NXEN
DENVER, CO / ACCESSWIRE / October 19, 2018 / Nexien BioPharma Inc. (OTCQB: NXEN) (formerly Intiva BioPharma Inc.) (the “Company”) today announced that effective as of October 19, 2018, the Company will trade on the OTCQB under the new stock symbol NXEN.
Commenting on the symbol change, Alain Bankier, the Interim CEO of Nexien stated, “The new symbol, NXEN, is more reflective of our Corporate name, Nexien BioPharma, and our objective of being a global leader in the further evolution of cannabinoid science and the development of Food and Drug Administration (“FDA”) compliant pharmaceuticals based on specific cannabinoid molecules.”
About Nexien BioPharma
Nexien BioPharma is a US-based pharmaceutical development company engaged in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (“FDA”) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.
Nexien BioPharma’s drug development strategy consists of:
| ● | The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations; |
| ● | Conducting “freedom to operate” investigations on these conditions; |
| ● | The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents; |
| ● | Identifying the regulatory pathway with the FDA; and |
| ● | Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s). |
Current financial disclosure and Real-Time Level 2 quotes for Nexien Biopharma are available at www.otcmarkets.com or at www.INTIVABioPharma.com.
Nexien Disclosure Notice: This press release contains “forward-looking statements. For this purpose, any statements contained herein or which are otherwise made by or on behalf of Nexien BioPharma that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties, which may cause results to differ materially from those, set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; Nexien BioPharma’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to events outside of Nexien BioPharma’s control.
Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. Nexien BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
Company Contact:
Mark Lubchenco
Director of Investor Relations
Nexien BioPharma Inc.
Phone: +1 303 495 7583
Email mlubchenco@NEXIENbiopharma.com
Website: www.NEXIENbiopharma.com